# IMRALDI™ (adalimumab)
Keywords: adalimumab, biosimilar, anti-TNF therapy, rheumatoid arthritis, psoriatic arthritis, axial spondyloarthritis, plaque psoriasis, hidradenitis suppurativa, Crohn's disease, ulcerative colitis, uveitis, juvenile idiopathic arthritis, paediatric plaque psoriasis

> IMRALDI™ is a biosimilar therapy containing adalimumab, designed for the treatment of various inflammatory conditions in adults and children. It is administered subcutaneously and has been validated through comprehensive studies to ensure efficacy and safety comparable to the originator adalimumab.

## Details
- [IMRALDI™ Overview](#): IMRALDI™ is a biosimilar anti-TNF therapy indicated for multiple inflammatory conditions in adults and children.
- [Licensed Indications](#): IMRALDI™ is approved for conditions such as rheumatoid arthritis, psoriatic arthritis, axial spondyloarthritis, plaque psoriasis, hidradenitis suppurativa, Crohn's disease, ulcerative colitis, and uveitis in adults, as well as juvenile idiopathic arthritis and other conditions in paediatric patients.
- [Marketing Authorisation](#): IMRALDI™ received EU approval based on rigorous non-clinical and clinical comparability studies with the originator adalimumab.
- [Resources](#): Includes instructional videos for syringe and pen injection methods.
- [Adverse Event Reporting](#): Details on how to report adverse events in the UK and Ireland.
- [Related Products](#): BENEPALI™ (etanercept) and FLIXABI™ (infliximab) are other biosimilar therapies marketed by Biogen.